Comparative In Vitro Evaluation of Commercially Available Pantoprazole Tablets
DOI:
https://doi.org/10.3126/kuset.v3i1.64175Abstract
Comparative study on in vitro evaluations (hardness, friability, weight variation, assay, disintegration, and dissolution tests) of marketed pantoprazole tablets (2 batches of each) from WHO GMP certified Nepalese companies (encoded with BP-02-A1, BP-02-A2), non-GMP certified Nepalese companies (encoded with BP-02-B1, BP-02-B2), and multinational companies (encoded with BP-02-C1, BP-02-C2) were done. The result of hardness, friability, weight variation, and assay and disintegration tests of all marketed products comply with pharmacopoeial limit. However, BP-02-A2 showed the fastest disintegration. Moreover, the comparison of percentage drug release of these companies on the basis of dissolution study demonstrated that BP-02-A2 (90 % drug release) complied best with standard RDRL protocol while BP-02-B2 (78% drug release) does not comply with above specification.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
![Creative Commons License](http://i.creativecommons.org/l/by-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.